

Association of Candida and its antifungal susceptibility pattern in patients with pulmonary tuberculosis

Kavitha Y¹, Khaja Moinuddin^{2*}, Anandi V.³, Hajaabdul Nazeer⁴

¹Assistant Professor, ²Tutor, ^{3,4}Professor, Dept. of Microbiology, VMMC & H, Karaikal

***Corresponding Author:**

Email: moinnnewlook@gmail.com

Abstract

Aim: The purpose of this study was to determine the incidence of Candida species and antifungal susceptibility pattern among smear positive pulmonary tuberculosis patients in a coastal tertiary care teaching hospital.

Materials and Method: One hundred and twenty one sputum samples were found to be positive for acid fast bacilli by Ziehl-Neelsen stain. All positive sputum samples were taken into consideration and subjected to standard mycological procedures.

Results: Out of 121 patients sputum samples positive for acid fast bacilli, Candida co infection was revealed in 41 samples (33.89%). Candida albicans was the most common species isolated and accounted for 60.98% followed by C.tropicalis (21.95%), C.krusei (9.76%) and C.glabrata (7.31%). Out of 539 AFB negative sputum samples, 107 (19.85%) samples yielded the growth of Candida. Candida albicans 69 (64.49%) was the most commonest species followed by Candida tropicalis 35 (32.71%). Majority of C.albicans and C.tropicalis were showed resistance to azole group. Only 52% of susceptibility exhibited towards fluconazole and clotrimazole by Candida albicans. Susceptibility of C.tropicalis towards fluconazole (55%) and clotrimazole (33%) was also high. All strains of C.krusei and C.glabrata were showed susceptibility to azole group as well as amphotericin B. Few strains of C.albicans (12%) and C.tropicalis (12%) were shown resistance to amphotericin B.

Conclusion: Candida co infection was found in 33.8% of 121 AFB proven pulmonary tuberculosis patients. Antifungal susceptibility testing revealed resistance to tested azole drugs as well as to amphotericin B. Hence there is a need to perform the Antifungal susceptibility testing before administering antifungals.

Keywords: Candida albicans, CHROM agar, Tuberculosis.

Introduction

Tuberculosis is one of the oldest infectious diseases. India is the country with the highest burden of TB. The World Health Organisation (WHO) TB statistics for India for 2015 give an estimated incidence figure of 2.2 million cases of TB for India out of a global incidence of 9.6 million.⁽¹⁾ Progress of the disease and prolonged treatment with antibiotics or immunosuppressive agents makes tuberculosis patients immunocompromised and hence susceptible to opportunistic infections.⁽²⁾ The incidence of opportunistic fungi has dramatically increased in past few years. The rate of opportunistic fungal infections in tuberculous patients is also very high.⁽³⁾ Candida albicans is the most commonly isolated fungal pathogen and may cause severe secondary infections.⁽⁴⁾ Nine to eighty percentages of pulmonary tuberculosis patients are infected by Candida species.^(2,3,5) polysaccharide fraction of C. albicans for enhance the growth as well as reduce the generation time of tubercle bacilli.⁽³⁾ In recent years, there is a great concern in probing disturbed fungal respiratory flora and its importance in pulmonary tuberculosis patients.⁽⁶⁾ Though Candida albicans persists to be the foremost species in pulmonary candidiasis, other Candida species are also being reported frequently. Few of them are associated with particular risk factors or groups of patients.⁽⁷⁾ Antifungal susceptibility varies from species to species. Therefore, species level identification of Candida is important in treating candidiasis. Most commonly used drugs in treating candidiasis is azole group. Due to

prolonged usage of these drugs, drug resistance has emerged in C.albicans and other species of Candida. Amphotericin B, a polyene fungicidal agent is being used in treating serious fungal infection. But cost and dose related side effects limit its usage.⁽⁸⁾

In, this region, so far no study has been done on Candida speciation from sputum samples of AFB positive. Hence, we aimed to determine the incidence of candida co infection among tuberculosis patients and their antifungal susceptibility.

Materials and Method

This is a prospective study in which a total of 660 sputum samples were collected from patients suspected of tuberculosis over a period of nine months (January 2016 to September 2016) in the department of microbiology, Vinayaka missions medical college and hospital. A total of 121 patients sputum samples were found to be positive for acid fast bacilli by Ziehl-Neelsen stain. All tuberculosis positive samples were subjected to standard mycological identification for Candida species. Direct examination was done by 10% KOH mount and Grams stain. For culture specimens were inoculated onto sabouraud's dextrose agar with chloramphenicol and the SDA slants were observed daily for the presence of growth. If there was no growth for 4 weeks, they were discarded. Kahanpaas Criteria was used in evaluating growth Criteria for diagnosis of candida infection. Kahanpaa criteria includes, 1) Colonies of Candida should be not less than thirty on sabouraud's dextrose agar. 2) Sight of budding yeast

cells, pus cells along with pseudohyphae in Gram stained smears.⁽⁹⁾

All the samples satisfied the criteria of Khanna et al⁽⁹⁾ were included. Further speciation of *Candida* was done by using CHROM agar. Inoculated plates of CHROM agar plates were incubated for 48 hours at 37°C and the colonies were identified based on the color produced by the *Candida* species. Light green colonies- *Candida albicans*, blue colonies with pink halo - *Candida tropicalis*, purple colonies- *Candida glabrata* and pink colonies- *Candida krusei*.

Antifungal susceptibility test was performed as per CLSI recommendations in document M44-A.⁽¹⁰⁾ Following antifungal discs were used: Fluconazole, clotrimazole, itraconazole, ketaconazole, Amphotericin B.

Quality control strain: *C. albicans* (ATCC90028)

No other species of *Candida* are used for quality control.

Results

A total of 121 patient's sputum samples were found to be positive for acid fast bacilli. There were 100 (82.64%) male and 21 (17.35%) female patients. In AFB positive sputum samples, association of *Candida* was revealed in 41 patients (33.89%).(Table 1)

Table 1: Age and sex wise distribution of *Candida* speciation among tuberculosis patients

Age	Male	Female	Total	<i>Candida</i> (n=41)
1-20	3	2	5	-
21-30	7	4	11	3(7.31%)
31-40	24	6	30	5(12.20%)
41-50	26	6	32	9(21.95%)
51-60	29	3	32	21(51.22)
61-70	11	-	11	3(7.31%)

Most common species was *Candida albicans* and accounted for 60.98%. Among non *albicans*, *C.tropicalis*(21.95%) was predominant followed by *C.krusei*(9.76%) and *C.glabrata*(7.31%).(Table 2)

Table 2: Distribution of various species among tuberculosis patients

<i>Candida</i> species	Number
<i>C.albicans</i>	25(60.98%)
<i>C.tropicalis</i>	9(21.95%)
<i>C.krusei</i>	4(9.76%)
<i>C.glabrata</i>	3(7.31%)
Total	41(100%)

Out of 539 AFB negative sputum samples, 107(19.85%) samples yielded the growth of *Candida*. *Candida albicans* 69 (64.49%) was the most commonest species followed by *Candida tropicalis* 35(32.71%). *Candida glabrata* 4(3.74%) was the least common pathogen isolated.

Antifungal susceptibility pattern showed, majority of *Candida albicans* and *C.tropicalis* strains showed resistance to commonly used azole group antifungal agents. Among azole group, itraconazole was found to be effective and its susceptibility ranged between 92%-100%. Three strains of *Candida albicans* were resistant to all tested antifungal agents and only one strain of *Candida tropicalis* showed resistance all drugs tested. Susceptibility to amphotericin B was high against both *C.albicans* and *C.tropicalis* accounted for 88%. No drug resistance was recorded in *C.krusei* and *C.glabrata*.(Table 3)

Table 3: Antifungal Susceptibility Pattern of *Candida* isolates

<i>Candida</i> species	Fluconazole	Clotrimazole	Itraconazole	Ketakonazole	AmphotericinB
<i>C.albicans</i> ⁽²⁵⁾	13(52%)	13(52%)	23(92%)	21(84%)	22(88%)
<i>C.tropicalis</i> ⁽⁹⁾	5(55.5%)	3(33.33%)	8(88.88%)	6(66.66%)	8(88.8%)
<i>C.krusei</i> ⁽⁴⁾	4(100%)	4(100%)	4(100%)	4(100%)	4(100%)
<i>C.glabrata</i> ⁽³⁾	3(100%)	3(100%)	3(100%)	3(100%)	3(100%)

Discussion

Various studies revealed the association of *Candida* in sputum samples of patients with pulmonary tuberculosis. This association in different studies varied from nine to eighty percent.⁽⁵⁾ The present study revealed 33.89% *Candida* co infection. As per Jain et al,⁽⁷⁾ *Candida* co infection in pulmonary tuberculosis patients was 23.57%. In our study, *Candida albicans* (60.98%) was the most common species followed by *Candida tropicalis* (21.95%). Except in some studies, *C. albicans* has been reported as the predominant isolate from sputum samples of tuberculosis patients followed by *C. tropicalis*.^(6,7) *Candida krusei* and *Candida glabrata* was accounted only for 9.76% and 7.31% respectively. As per Arunava kali et al, *C.albicans* was the common species isolated and accounted upto 50% followed by *C.tropicalis*(20%) and *C.glabrata* (20%). Least commonly isolated species were *C. parapsilosis*(6.7%) and *C. krusei*(3.3%).⁽¹¹⁾ As per Grower et al *Candida tropicalis* in 4(4%) and *Candida parapsilosis* in 2 (2%) in their series of 100 cases.⁽¹²⁾ According to Baradkar et al. *C. tropicalis* 3.25%, *Candida parapsilosis* 3.25%.⁽⁵⁾ These

variations in isolation rates are probably due to differences in local prevalence of different species due to different environmental factors, as well as various identification techniques employed.⁽⁹⁾

Antifungal susceptibility pattern of the *Candida* species have been discussed and shown to have resistance to both azoles and Amphotericin B antifungal. So the alternative antifungal regimens are essential and the function of other combinations of antifungals in treating serious *Candida* infections needs to be assessed.⁽¹³⁾ In our study, drug resistance was noticed in *C.albicans* and *C.tropicalis* towards azole group (76%) and amphotericin B(66%).

As per Kul KO et al.⁽¹⁴⁾ *C.albicans* showed, fluconazole resistance in 2% and itraconazole resistance in 6%. According to KK Prabsobh and Udhaya , quite high level percentage (48%) of the resistance towards the antifungal drug Nystatin was observed from all the *Candida* species followed by Azole drug (24%) and Amphotericin B (22%).⁽¹⁵⁾

It was observed that the emergence of antifungal resistance to single drug or to multiple drugs in *Candida* species. Three stains of *C.albicans* and one strain of *C.tropicalis* were resistant to all antifungal agents used. It was found to be difficult to treat such secondary infections in immunocompromised patients and lead to therapeutic failure because of association with multi drug resistance. Such multi drug resistance *Candida* species increasing morbidity and mortality in immunocompromised patients.

Conclusion

Incidence of *Candida* infection among pulmonary tuberculosis was 33%. Antifungal susceptibility pattern revealed drug resistance to commonly used antifungal agents. Appropriate antifungal agent should be chosen to treat *Candida* infection in pulmonary tuberculosis after obtaining susceptibility results.

References

1. Global Tuberculosis Control 2015, WHO, Geneva, 2015 www.who.int/tb/publications/global_report.
2. Phukan AC, Sarmabordoloi JN, Mahanta J. Bronchopulmonary candidiasis in a tertiary referral hospital of Assam, India. *Ind J Med Sci* 2000;54:491-494.
3. Naz SA, Tariq P. A study of the trend in prevalence of opportunistic Candidal coinfections among patients of pulmonary tuberculosis. *Pak J Bot.* 2004;36:857-62.
4. Chakrabarti A, Chatterjee SS, Shivaprakash MR. Overview of opportunistic fungal infections in India. *Jpn J Med Mycol* 2008;49:165-172.
5. Baradkar VP, Mathur M, Wanjari K, Kumar S. *Candida* in pulmonary tuberculosis. *Bombay Hosp J* 2009; (special issue):52-53.
6. Latha R, Sasikala R, Muruganandam N, Venkatesh Babu R. Study on the shifting patterns of Non *Candida albicans* *Candida* in lower respiratory tract infections and evaluation of the CHRO Magar in identification of the *Candida* species. *J Microbiol Biotech Res.* 2011;1:4-9.
7. Jain SK, Agrawal RL, Sharma DA, Agrawal M. *Candida* in pulmonary tuberculosis. *J Postgrad Med.* 1982 Jan;28(1):24-9.
8. Mohan, S., and Karthikeyan, D. Speciation and Antifungal Susceptibility Pattern of *Candida* Isolated from Clinical Specimens. *Int.J.Curr.Microbiol.App.Sci.*2016;5(4):820-824.
9. Khanna BK, Nath P, Ansari AH. A study of mycotic flora of respiratory tract in pulmonary tuberculosis. *Ind J Tuberc* 1977;24:159-62.
10. Wayne Pa.(2004) National committee for antifungal disk diffusion susceptibility testing yeast: approved guidelines CLSI:M-44A.
11. Kali A, Charles MP, Noyal MJ, Sivaraman U, Kumar S and Easow JM. Prevalence of *Candida* co-infection in patients with pulmonary tuberculosis. *Australas Med J* 2013;6(8):387-91.
12. Grower S, Junnarkar RV. Mycological flora in sputum of patients suffering from bronchopulmonary diseases. *Ind J Med Sci* 1965;19:823-27.
13. Mannur SY, Devi AD, Nagaraj ER. Antifungal susceptibility pattern of *Candida* species isolated from suspected cases of tuberculosis. *Indian J Microbiol Res.*2016;3(3):219-223.
14. Kul'ko AB, Mitrokhin SD, Moroz AM. Respiratory tract mycotic infection in physiological practice: species composition and susceptibility of the *Candida* clinical isolates to antifungal agents. *Antibiot Khimioter* 2005;50:14-17.
15. K.K. Prasobh and V. Udhaya. Occurrence of Drug Resistant *Candida* Species in the Sputum of TB Clinic Attendees in and Around Chidambaram, Tamil Nadu, India. *J. Exp. Sci.*2010;1(4):43-47.

How to cite this article: Kavitha Y., Moinuddin K., Anandi V., Nazeer H. Association of *Candida* and its antifungal susceptibility pattern in patients with pulmonary tuberculosis. *International Journal of Medical Microbiology and Tropical Diseases* 2017;3(3):126-128.